German biotech firm CureVac has filed a lawsuit against Moderna in Delaware, alleging patent infringement of its mRNA technology in Moderna's COVID-19 vaccine, Spikevax. The case is among several ...

Now, it’s worth noting Stock Advisor’s total average return is 986 % — a market-crushing outperformance compared to 199% for ...

US biotech Moderna today announced that the European Commission (EC) has granted marketing authorization for mCOMBRIAX ...

Matthew Herper covers medical innovation — both its promise and its perils. Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall ...

A few years ago, investors rushed to buy Moderna (NASDAQ: MRNA) stock. The biotech company had brought its coronavirus vaccine to market in less than a year and quickly saw earnings take off. The ...

Shares of Moderna (MRNA) have surged sharply this week, drawing renewed attention to exchange traded funds with significant exposure to the U.S. pharmaceutical and biotechnology company. The stock ...

The US risks falling behind in biotechnology as the government cuts funding and skepticism over vaccines grows, according to Moderna Inc.’s co-founder and Chairman Noubar Afeyan. “It’s an unfortunate ...

Moderna’s earnings and stock price climbed during early pandemic days -- that’s as demand for the company’s coronavirus vaccine soared. Since, the company has faced various challenges that have ...

Massachusetts-based Moderna Inc. (NASDAQ: MRNA) is seeing fresh momentum in recent weeks, with the stock off to a flying start in 2026. The company that rose to prominence during the COVID-19 pandemic ...

Doubling survival in pancreatic cancer, a long-fought rare disease approval, a massive IPO and ambitious biotech ...